<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: investment", fill: "#ff1493"},
{source: "1: investment", target: "1: common stock", fill: "#ff1493"},
{source: "1: investment", target: "7: trials may fail", fill: "#062a78"},
{source: "7: trials may fail", target: "7: demonstrate", fill: "#062a78"},
{source: "7: demonstrate", target: "7: candidates", fill: "#062a78"},
{source: "7: candidates", target: "7: which could prevent", fill: "#062a78"},
{source: "7: which could prevent", target: "7: significantly delay", fill: "#062a78"},
{source: "7: significantly delay", target: "7: regulatory approval", fill: "#062a78"},
{source: "7: trials may fail", target: "9: development", fill: "#e6be8a"},
{source: "9: development", target: "9: commercialization", fill: "#e6be8a"},
{source: "9: development", target: "11: development", fill: "#004040"},
{source: "11: development", target: "11: clinical trial efforts will", fill: "#004040"},
{source: "11: clinical trial efforts will", target: "11: viable new products", fill: "#004040"},
{source: "11: development", target: "13: Phase II ", fill: "#6d9bc3"},
{source: "13: Phase II ", target: "13: clinical trials with", fill: "#6d9bc3"},
{source: "13: clinical trials with", target: "13: postherpetic", fill: "#6d9bc3"},
{source: "13: postherpetic", target: "13: discontinuing", fill: "#6d9bc3"},
{source: "13: discontinuing", target: "13: development", fill: "#6d9bc3"},
{source: "13: development", target: "13: medication", fill: "#6d9bc3"},
{source: "13: Phase II ", target: "15: clinical trials", fill: "#d2691e"},
{source: "15: clinical trials", target: "15: product candidates", fill: "#d2691e"},
{source: "15: product candidates", target: "15: may severely harm", fill: "#d2691e"},
{source: "15: clinical trials", target: "16: regulatory approval", fill: "#fd0e35"},
{source: "16: regulatory approval", target: "16: potential products", fill: "#fd0e35"},
{source: "16: potential products", target: "16: future strategic", fill: "#fd0e35"},
{source: "16: future strategic", target: "16: strategic partners", fill: "#fd0e35"},
{source: "16: strategic partners", target: "16: licensees must", fill: "#fd0e35"},
{source: "16: licensees must", target: "16: product candidates", fill: "#fd0e35"},
{source: "16: product candidates", target: "16: demonstrate", fill: "#fd0e35"},
{source: "16: regulatory approval", target: "22: pharmaceutical", fill: "#ffa343"},
{source: "22: pharmaceutical", target: "22: biotechnology", fill: "#ffa343"},
{source: "22: biotechnology", target: "22: industries", fill: "#ffa343"},
{source: "22: industries", target: "22: suffered significant setbacks", fill: "#ffa343"},
{source: "22: suffered significant setbacks", target: "22: late stage clinical trials", fill: "#ffa343"},
{source: "22: late stage clinical trials", target: "22: earlier development activities", fill: "#ffa343"},
{source: "22: pharmaceutical", target: "START_HERE", fill: "#ffa343"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Protest demonstrations</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Controlled_clinical_trials">Controlled clinical trials</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MyPlate">MyPlate</a></td>
      <td>MyPlate is the current nutrition guide published by the USDA's Center for Nutrition Policy and Promotion, and serves as a recommendation based on the Dietary Guidelines for Americans. It replaced the USDA's MyPyramid guide on June 2, 2011, ending 19 years of USDA food pyramid diagrams.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/AccuPoll">AccuPoll</a></td>
      <td>AccuPoll is an American company that engages in the design, development, and sale of electronic voting system.  Their associated products and services are for use in federal,\nstate, local, and private elections in the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>RENOVIS INC      Item 1A Risk Factors        An  <font color="blue">investment</font> in our <font color="blue">common stock</font> is very risky</td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font>     consider  the  risks  described  below, together with all of the other     information in this report before making a decision to invest in our common     stock</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occur, our business, financial     condition, results of <font color="blue">operations</font> and <font color="blue">growth prospects could</font> be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>In this case, the <font color="blue">trading price</font> of our <font color="blue">common stock</font> could decline     and  you  may lose all or part of your <font color="blue">investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font>, not presently known to us, or that we     presently deem as immaterial, may also <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>If any     of these <font color="blue">additional</font> risks and <font color="blue">uncertainties</font> occur, the <font color="blue">trading price</font> of our     common  stock  could  decline,  and you might lose all or part of your     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Company        Clinical <font color="blue">trials may fail</font> to <font color="blue">demonstrate</font> the safety and efficacy of our     product  <font color="blue">candidates</font>,  <font color="blue">which could prevent</font> or <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> delay</font> their     <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success</font> is dependent upon, among other factors, our ability to     develop working products and our ability to <font color="blue">successfully</font> complete clinical     trials</td>
    </tr>
    <tr>
      <td>All of our <font color="blue"><font color="blue">potential product</font>s</font> currently are in research, preclinical     <font color="blue">development</font> or <font color="blue">clinical testing</font>, and <font color="blue">commercialization</font> of those products     will not occur for at least the next several years, if at all</td>
    </tr>
    <tr>
      <td>All of our     potential  products  will  require  extensive  <font color="blue">additional</font> research and     <font color="blue">development</font> prior to any <font color="blue">commercial <font color="blue">introduction</font></font></td>
    </tr>
    <tr>
      <td>There can be no assurance     that any of our research and <font color="blue">development</font> and <font color="blue"><font color="blue">clinical trial</font> efforts will</font>     result in <font color="blue">viable <font color="blue">new products</font></font></td>
    </tr>
    <tr>
      <td>For example, in July 2004, we announced our     decision to <font color="blue"><font color="blue">discontinue</font> efforts</font> to <font color="blue">commercialize</font> REN-213, an <font color="blue">intravenous</font>     drug candidate we were developing for the treatment of acute post-operative     pain</td>
    </tr>
    <tr>
      <td>In August 2005, based on results of our <font color="blue">Phase II </font><font color="blue"><font color="blue"><font color="blue">clinical trial</font>s</font> with</font>     REN-1654 in patient volunteers with post-herpetic neuralgia and sciatica, we     announced that we were <font color="blue">discontinuing</font> <font color="blue">development</font> of REN-1654 as an oral     <font color="blue">medication</font></td>
    </tr>
    <tr>
      <td>In June 2005 we announced our decision to <font color="blue"><font color="blue">discontinue</font> efforts</font> to     develop REN-850 for the treatment of <font color="blue">multiple sclerosis</font></td>
    </tr>
    <tr>
      <td>Any failure or substantial delay in completing <font color="blue"><font color="blue">clinical trial</font>s</font> for our     product <font color="blue">candidates</font>, including NXY-059, <font color="blue">may <font color="blue">severely harm</font></font> our business</td>
    </tr>
    <tr>
      <td>Before obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> for the sale of any of our potential     products or the <font color="blue"><font color="blue">potential product</font>s</font> of our current and <font color="blue">future strategic</font>     partners and licensees, we and our <font color="blue"><font color="blue">strategic partner</font>s</font> or <font color="blue">licensees must</font>     subject these product <font color="blue">candidates</font> to extensive preclinical and clinical     testing to <font color="blue">demonstrate</font> their safety and efficacy in humans</td>
    </tr>
    <tr>
      <td>The success of     this preclinical and <font color="blue">clinical testing</font> is critical to achieving our product     <font color="blue">development</font> goals</td>
    </tr>
    <tr>
      <td>If our product <font color="blue">development</font> efforts are <font color="blue">unsuccessful</font>, we     will not obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for them, we will not <font color="blue">generate sales</font>     from them, and our business and results of <font color="blue">operations</font> would be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Clinical trials are expensive, time-consuming and typically take years to     complete</td>
    </tr>
    <tr>
      <td>In connection with <font color="blue"><font color="blue">clinical trial</font>s</font>, we face the risks that:           •   a <font color="blue">product candidate</font> may not prove to be <font color="blue">efficacious</font>;           •   we <font color="blue">may discover</font> that a <font color="blue">product candidate</font> may cause harmful side     effects;           •   <font color="blue">patients may</font> die or suffer other <font color="blue">adverse medical effects</font> for reasons     that may not be related to the <font color="blue">product candidate</font> being tested;           •   the results may not confirm the positive results of <font color="blue">earlier trials</font>;     and           •   the results may not meet the level of <font color="blue">statistical significance</font>     required by the FDA or other <font color="blue"><font color="blue">regulatory</font> agencies</font></td>
    </tr>
    <tr>
      <td>The results in <font color="blue">early phases</font> of <font color="blue">clinical testing</font> are <font color="blue">based upon</font> limited     numbers of patients and a limited follow-up period and our <font color="blue">success may</font> not     be <font color="blue">indicative</font> of results in a large number of patients or long-term                                           16     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>efficacy</td>
    </tr>
    <tr>
      <td>A number of companies in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     <font color="blue">industries</font> have <font color="blue">suffered <font color="blue">significant</font> setbacks</font> in late stage <font color="blue"><font color="blue">clinical trial</font>s</font>     even after achieving promising results in earlier <font color="blue">development</font> <font color="blue">activities</font>,     including previous late-stage <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The results from the Phase     III SAINT I trial for NXY-059 may not be predictive of results obtained in     the second <font color="blue">Phase III </font><font color="blue">clinical trial</font>, SAINT II If a larger population of     patients does not experience positive results, or if these results do not     have a lasting effect, our products may not receive approval from the FDA     In addition, even if the <font color="blue">primary endpoint</font> of the SAINT II trial is achieved,     if the SAINT II trial does not <font color="blue">demonstrate</font> positive trends or <font color="blue">statistically</font>     <font color="blue"><font color="blue">significant</font> benefits <font color="blue">with respect</font></font> to <font color="blue">neurological impairment measured using</font>     the NIHSS, our ability to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for NXY-059 in certain     <font color="blue">jurisdictions</font>  outside  <font color="blue">the <font color="blue"><font color="blue">United States</font> </font></font>could be impaired and market     <font color="blue">acceptance</font> for NXY-059 could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>The <font color="blue">potential market</font>     <font color="blue">opportunity</font> for NXY-059 <font color="blue">will also likely depend</font> in part on whether NXY-059     may be labeled for <font color="blue">administration prior</font> to a CT scan</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">demonstrate</font>     the safety and <font color="blue">effective</font>ness of our product <font color="blue">candidates</font> in larger patient     <font color="blue">populations</font> could have a material adverse effect on our business that would     cause our stock price to decline <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  enroll  patients  for <font color="blue"><font color="blue">clinical trial</font>s</font> may cause delays in     developing our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter delays</font> or <font color="blue">rejections</font> if we, our <font color="blue"><font color="blue">strategic partner</font>s</font> or     licensees are unable to <font color="blue">enroll enough patients</font> to complete <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Patient  </font>enrollment depends on many factors, including the size of the     <font color="blue">patient population</font>, the nature of the protocol, the proximity of patients to     <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the trial and the number and     size of ongoing <font color="blue"><font color="blue">clinical trial</font>s</font> sponsored by others that seek to enroll     similar  patients</td>
    </tr>
    <tr>
      <td>When one <font color="blue">product candidate</font> is evaluated in multiple     <font color="blue"><font color="blue">clinical trial</font>s</font> simultaneously, <font color="blue">patient enrollment</font> in <font color="blue">ongoing trials</font> can be     <font color="blue">adversely</font> affected by negative results from completed trials</td>
    </tr>
    <tr>
      <td>At various     times, NXY-059 has <font color="blue">been involved</font> in multiple <font color="blue"><font color="blue">clinical trial</font>s</font> that were     <font color="blue">enrolling patients simultaneously</font></td>
    </tr>
    <tr>
      <td>Any delays in planned <font color="blue">patient enrollment</font>     may result in <font color="blue">increased costs</font> and delays, which could harm our ability to     develop products</td>
    </tr>
    <tr>
      <td>The <font color="blue">independent</font> clinical <font color="blue">investigators</font> and <font color="blue"><font color="blue">contract research</font> <font color="blue">organizations</font></font>     that  we  and our <font color="blue"><font color="blue">strategic partner</font>s</font> or <font color="blue">licensees rely upon</font> to conduct     clinical  trials  may not be diligent, careful or timely, and may make     mistakes in the conduct of our trials</td>
    </tr>
    <tr>
      <td>We  <font color="blue"><font color="blue">depend on</font> <font color="blue">independent</font> clinical <font color="blue">investigators</font></font> and <font color="blue">contract research</font>     <font color="blue">organizations</font> (CROs) to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font> under their <font color="blue">agreements</font>     with us or, in the case of NXY-059, with AstraZeneca</td>
    </tr>
    <tr>
      <td>We are not employing     these <font color="blue">investigators</font>, and we <font color="blue">cannot control</font> the amount or timing of resources     that they devote to our programs</td>
    </tr>
    <tr>
      <td>Our <font color="blue">contracts with</font> these <font color="blue">investigators</font>     involve fixed fees</td>
    </tr>
    <tr>
      <td>If the costs of performing the <font color="blue"><font color="blue">clinical trial</font>s</font> exceed     estimates,  these <font color="blue">investigators</font> may fail to devote sufficient time and     resources to our drug <font color="blue">development</font> programs, fail to enroll patients as     rapidly as expected, or otherwise fail to perform in a satisfactory manner,     <font color="blue"><font color="blue">regulatory</font> approval</font> and our <font color="blue"><font color="blue">introduction</font>s</font> of <font color="blue"><font color="blue">new products</font> will</font> be delayed</td>
    </tr>
    <tr>
      <td>We <font color="blue">contract with</font> CROs for execution of our <font color="blue"><font color="blue">clinical trial</font>s</font> for our product     <font color="blue">candidates</font> other than NXY-059</td>
    </tr>
    <tr>
      <td><font color="blue">Failure of the CROs </font>to meet their <font color="blue">obligations</font>     could <font color="blue">adversely</font> affect clinical <font color="blue">development</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Moreover,  these  <font color="blue">independent</font>  <font color="blue">investigators</font>  and  CROs  may also have     <font color="blue"><font color="blue">relationship</font>s with</font> other <font color="blue">commercial entities</font>, some of <font color="blue">which may compete with</font>     us</td>
    </tr>
    <tr>
      <td>If <font color="blue">independent</font> <font color="blue">investigators</font> and CROs assist our <font color="blue"><font color="blue">competitor</font>s</font>, it could     harm our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our licensee, AstraZeneca, for the <font color="blue">completion</font> of the NXY-059     <font color="blue">clinical program</font> and for the <font color="blue">commercialization</font> of NXY-059</td>
    </tr>
    <tr>
      <td>Under our <font color="blue">exclusive license agreement with</font> AstraZeneca, <font color="blue">AstraZeneca </font>is     responsible for all aspects of clinical <font color="blue">development</font> of NXY-059</td>
    </tr>
    <tr>
      <td>If NXY-059     receives <font color="blue"><font color="blue">regulatory</font> approval</font>, <font color="blue">AstraZeneca </font>will be responsible for marketing     and sales of the <font color="blue">commercial product</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">AstraZeneca </font>is responsible for     these functions, we have <font color="blue">no <font color="blue">control over</font></font> the <font color="blue">development</font> schedule or, if     NXY-059 receives <font color="blue"><font color="blue">regulatory</font> approval</font>, the marketing plan for NXY-059</td>
    </tr>
    <tr>
      <td>If the     clinical  trials  for  NXY-059 are not successful, NXY-059 will not be     <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>Moreover, if <font color="blue">AstraZeneca </font>elects to terminate the clinical     program for NXY-059, the rights to develop and market NXY-059 <font color="blue">will revert</font> to     us</td>
    </tr>
    <tr>
      <td>If these <font color="blue">rights revert</font> to us, we will have to fund the <font color="blue">clinical program</font>s     for NXY-059 on our own, seek a <font color="blue">strategic partner</font> or licensee for clinical     <font color="blue">development</font> or abandon NXY-059</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font>Our  reliance  on  <font color="blue">AstraZeneca </font> poses a number of risks, including the     following:           •   <font color="blue">AstraZeneca </font>has <font color="blue">discretion</font> to <font color="blue">elect whether</font> to pursue the <font color="blue">development</font>     of NXY-059 or to modify or abandon the <font color="blue">clinical program</font> at any time;           •   we <font color="blue">cannot control</font> whether <font color="blue">AstraZeneca </font><font color="blue">will <font color="blue">devote sufficient resources</font></font>     to the <font color="blue">clinical program</font> and, if NXY-059 is <font color="blue">approved by</font> the FDA or other     <font color="blue"><font color="blue">regulatory</font> agencies</font>, the marketing plan for the <font color="blue">commercial drug product</font>;           •   although we have no history of royalty payment disputes, even if     NXY-059 is approved and <font color="blue">commercialize</font>d, disputes may arise in the future     <font color="blue">with respect</font> to the <font color="blue">calculation</font> of <font color="blue">royalty payments based on net sales</font>     related to NXY-059; and           •   if <font color="blue">AstraZeneca </font>perceives that the market <font color="blue">opportunity</font> for NXY-059 or     its profit margin from the sale of NXY-059 is too small to justify     <font color="blue">commercialization</font>, the interests and <font color="blue">motivations</font> of <font color="blue">AstraZeneca </font>may not be,     or may not remain, aligned with ours</td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">risks materialize</font>, it <font color="blue">could delay</font> the <font color="blue">development</font> schedule     for NXY-059 and impair its <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>If we or our <font color="blue"><font color="blue">strategic partner</font>s</font> or <font color="blue">licensees fail</font> to obtain US <font color="blue">regulatory</font>     approvals for product <font color="blue">candidates</font> under <font color="blue">development</font>, including our lead     <font color="blue">product candidate</font>, NXY-059, we will not be able to <font color="blue">generate revenue</font> in the     US <font color="blue">market from</font> the <font color="blue">commercialization</font> of product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We must receive FDA approval for each of our product <font color="blue">candidates</font> before we     can <font color="blue">commercialize</font> or sell that <font color="blue">product candidate</font> in the <font color="blue">United States</font>, and     AstraZeneca, our licensee for NXY-059, must receive <font color="blue"><font color="blue">regulatory</font> approval</font> for     NXY-059 and <font color="blue">commercialize</font> or sell NXY-059 before we will receive royalties</td>
    </tr>
    <tr>
      <td>The FDA can limit or deny their approval for many reasons, including:           •   a <font color="blue">product candidate</font> may be found to be unsafe or <font color="blue">in<font color="blue">effective</font></font>;           •   <font color="blue">regulators may</font> interpret data from pre<font color="blue">clinical testing</font> and clinical     <font color="blue">trials differently</font> and <font color="blue">less favorably than</font> the way we interpret it;           •   <font color="blue">regulators may</font> not approve the <font color="blue"><font color="blue">manufacturing</font> processes</font> or <font color="blue">facilities</font>     that we or our <font color="blue"><font color="blue">strategic partner</font>s</font> or <font color="blue">licensees use</font>; and           •   <font color="blue">regulators may</font> change their <font color="blue">approval policies</font> or <font color="blue">adopt new</font>     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Failure to obtain FDA approval or any delay or setback in obtaining such     <font color="blue">approval could</font>:           •   <font color="blue">adversely</font> affect our ability to market any drugs we develop     <font color="blue">independent</font>ly or with <font color="blue"><font color="blue">strategic partner</font>s</font> or licensees;           •   impose <font color="blue">additional</font> costs and diminish any <font color="blue"><font color="blue">competitive advantage</font>s</font> that     we may attain; and           •   <font color="blue">adversely</font> affect our ability to <font color="blue">generate royalties</font> or product     revenues</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such failures</font> or delays in the <font color="blue"><font color="blue">regulatory</font> approval</font> process for any of     our  product <font color="blue">candidates</font> would delay or diminish our receipt of product     revenues,  if any, and would <font color="blue">materially</font> <font color="blue">adversely</font> affect our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Even if we obtain FDA approval, our <font color="blue">product candidate</font> may not be approved     for all <font color="blue">indications</font> that we request, which <font color="blue">could limit</font> the uses of our     product and <font color="blue">adversely</font> impact our <font color="blue">potential royalties</font> and <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>If     FDA  approval of a product is granted, such <font color="blue">approval may</font> be subject to     <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> for which the <font color="blue">product may</font> be marketed or     require costly, post-marketing follow-up studies</td>
    </tr>
    <tr>
      <td>As to any product for     <font color="blue">which marketing approval</font> is obtained, the labeling, packaging, adverse event     reporting, storage, advertising, promotion and record keeping related to the     <font color="blue">product will</font> be subject to extensive <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">The                                           </font>18     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font><font color="blue">subsequent discovery</font> of <font color="blue"><font color="blue">previously</font> unknown <font color="blue">problems with</font></font> the <font color="blue">product may</font>     result in <font color="blue"><font color="blue">restrictions</font> on</font> the product, including withdrawal of the product     from the market</td>
    </tr>
    <tr>
      <td>We may be slow to adapt, or we <font color="blue">may never adapt</font>, to changes     in <font color="blue">existing <font color="blue"><font color="blue">requirement</font>s</font></font> or adoption of <font color="blue">new <font color="blue"><font color="blue">requirement</font>s</font></font> or policies</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue"><font color="blue">comply with</font> applicable</font> US <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>, we may be     subject to fines, suspension or withdrawal of <font color="blue"><font color="blue">regulatory</font> approval</font>s, product     recalls,  seizure  of  products,  operating  <font color="blue">restrictions</font> and criminal     <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>If we or our <font color="blue"><font color="blue">strategic partner</font>s</font> or <font color="blue">licensees fail</font> to obtain <font color="blue">regulatory</font>     approvals in other countries for product <font color="blue">candidates</font> under <font color="blue">development</font>, we     will  not  be  able  to  generate  revenue  in <font color="blue">such countries from</font> the     <font color="blue">commercialization</font> of product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In order to market our <font color="blue">products outside</font> of the <font color="blue">United States</font>, we and our     <font color="blue"><font color="blue">strategic partner</font>s</font> and <font color="blue">licensees must</font> establish and <font color="blue"><font color="blue">comply with</font> numerous</font> and     varying <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> of other countries regarding safety and     efficacy</td>
    </tr>
    <tr>
      <td><font color="blue">Approval  </font>procedures  vary  <font color="blue">among countries</font> and can involve     <font color="blue">additional</font> product testing and <font color="blue">additional</font> administrative review periods</td>
    </tr>
    <tr>
      <td>The     time required to obtain approval in other <font color="blue">countries might differ from</font> that     required to obtain FDA approval</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">regulatory</font> approval</font> process in other     <font color="blue">countries may</font> include all of the <font color="blue">risks detailed</font> above regarding FDA approval     in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>approval in <font color="blue">one country</font> does not ensure     <font color="blue">regulatory</font>  approval  in  another, but a failure or delay in obtaining     <font color="blue"><font color="blue">regulatory</font> approval</font> in <font color="blue">one country</font> may negatively impact the <font color="blue">regulatory</font>     process in others</td>
    </tr>
    <tr>
      <td>Failure to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> in other countries     or any delay or setback in obtaining such <font color="blue">approval could</font> have the same     <font color="blue">adverse effects detailed</font> above regarding FDA approval in the <font color="blue">United States</font>,     including the risks that our <font color="blue">product candidate</font> may not be approved for all     <font color="blue">indications</font> that we request, which <font color="blue">could limit</font> the uses of our product and     <font color="blue">adversely</font> impact our <font color="blue">potential royalties</font> and <font color="blue">product sales</font>, and that such     <font color="blue">approval may</font> be subject to <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> for which the     <font color="blue">product may</font> be marketed or require costly, post-marketing follow-up studies</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue"><font color="blue">comply with</font> applicable</font> foreign <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>, we may     be subject to fines, suspension or withdrawal of <font color="blue"><font color="blue">regulatory</font> approval</font>s,     product recalls, seizure of products, operating <font color="blue">restrictions</font> and criminal     <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>Even if our product <font color="blue">candidates</font> are approved and <font color="blue">commercialize</font>d, competitive     products may impede market <font color="blue">acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>Hospitals, physicians or <font color="blue">patients may</font> conclude that our <font color="blue"><font color="blue">potential product</font>s</font>     are less safe or <font color="blue">effective</font> or <font color="blue">otherwise less attractive than existing drugs</font></td>
    </tr>
    <tr>
      <td>Even  if  approved  and <font color="blue">commercialize</font>d, NXY-059, or any <font color="blue">future product</font>     <font color="blue">candidates</font>, may fail to achieve market <font color="blue">acceptance</font> with hospitals, physicians     or  patients</td>
    </tr>
    <tr>
      <td>If our products do not receive market <font color="blue">acceptance</font> for any     reason, our <font color="blue">revenue potential could</font> be <font color="blue">diminished which would <font color="blue">materially</font></font>     <font color="blue">adversely</font>  affect  our  business,  financial  condition and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further,  our  <font color="blue"><font color="blue">competitor</font>s</font> may develop <font color="blue">new products</font> that could be more     <font color="blue">effective</font> or <font color="blue">less costly</font>, or that may seem more cost-<font color="blue">effective</font>, than our     products</td>
    </tr>
    <tr>
      <td>For example, although we believe that NXY-059 would not face     <font color="blue">direct <font color="blue">competition</font> from products currently available</font> to <font color="blue">stroke victims</font>, a     number of <font color="blue">organizations</font> are conducting <font color="blue"><font color="blue">clinical trial</font>s</font> of <font color="blue">neuroprotectant</font>     drug <font color="blue">candidates</font> which, if approved and <font color="blue">commercialize</font>d, would compete with     NXY-059</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>developing <font color="blue">such products</font> include Astellas Pharma, Inc,     D-Pharm Ltd, IVAX Pharmaceuticals, Inc, Paion AG, Ferrer Grupo and Vertex     Pharmaceuticals Incorporated</td>
    </tr>
    <tr>
      <td>Most  of our <font color="blue"><font color="blue">competitor</font>s</font> have <font color="blue">substantially</font> greater capital resources,     research and <font color="blue">development</font> staffs, <font color="blue">facilities</font> and experience in conducting     clinical  trials  and  obtaining  <font color="blue">regulatory</font>  approvals, as well as in     <font color="blue">manufacturing</font> and marketing <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>As a result, they may     achieve product <font color="blue">commercialization</font> or <font color="blue">patent protection</font> earlier than we can,     if at all</td>
    </tr>
    <tr>
      <td>Hospitals, physicians, patients or the <font color="blue">medical community</font> in     <font color="blue">general may</font> not accept and use any products that we may develop</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>We have no experience selling, marketing or <font color="blue">distributing products</font> and no     <font color="blue">internal capability</font> to do so</td>
    </tr>
    <tr>
      <td>If we receive <font color="blue"><font color="blue">regulatory</font> approval</font> to <font color="blue">commence <font color="blue">commercial sale</font>s</font> of any of our     product <font color="blue">candidates</font> for which we have retained <font color="blue">marketing rights</font>, we will have     to establish a sales and <font color="blue"><font color="blue">marketing organization</font> with <font color="blue">appropriate</font> technical</font>     expertise and <font color="blue">supporting distribution capability</font></td>
    </tr>
    <tr>
      <td>At present, we have no     sales  or <font color="blue">marketing personnel</font></td>
    </tr>
    <tr>
      <td>Factors that may inhibit our efforts to     <font color="blue">commercialize</font> our products without <font color="blue"><font color="blue">strategic partner</font>s</font> or licensees include:           •   our <font color="blue">inability</font> to recruit and retain <font color="blue">adequate numbers</font> of <font color="blue">effective</font>     sales and <font color="blue">marketing personnel</font>;           •   the <font color="blue">inability</font> of <font color="blue">sales personnel</font> to obtain access to or persuade     <font color="blue">adequate numbers</font> of physicians to prescribe our products;           •   the lack of <font color="blue">complementary products</font> to be offered by <font color="blue">sales personnel</font>,     <font color="blue">which may put us at</font> a <font color="blue">competitive disadvantage against companies with</font>     <font color="blue">broader product lines</font>; and           •   <font color="blue">unforeseen costs associated with</font> creating an <font color="blue">independent</font> sales and     <font color="blue">marketing organization</font></td>
    </tr>
    <tr>
      <td>As an <font color="blue">alternative</font> to <font color="blue">establishing</font> our own sales and <font color="blue">marketing organization</font>,     we may engage a <font color="blue">pharmaceutical</font> or other <font color="blue">healthcare company with</font> an existing     <font color="blue">distribution system</font> and <font color="blue">direct sales organization</font> to <font color="blue">assist us</font></td>
    </tr>
    <tr>
      <td>We may not     be able to <font color="blue">successfully</font> establish sales and <font color="blue">distribution <font color="blue">capabilities</font> either</font>     on our own or in <font color="blue"><font color="blue">collaboration</font> with <font color="blue">third parties</font></font> or gain market <font color="blue">acceptance</font>     for our products</td>
    </tr>
    <tr>
      <td>To the extent we enter co-promotion or other licensing     <font color="blue">arrangements</font>, any revenues we receive will <font color="blue">depend on</font> the efforts of third     parties and we may not succeed</td>
    </tr>
    <tr>
      <td>If our partners, licensees or <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>rs</font></font> of our <font color="blue">products fail</font> to     devote  sufficient  time  and  resources  to our concerns, or if their     performance is substandard, our <font color="blue"><font color="blue">clinical trial</font>s</font> and product <font color="blue"><font color="blue">introduction</font>s</font>     may be delayed and our <font color="blue">costs may rise</font></td>
    </tr>
    <tr>
      <td>We  have no <font color="blue">manufacturing</font> <font color="blue">facilities</font>, and we have no experience in the     commercial  <font color="blue">manufacturing</font> of drugs and no experience in <font color="blue">designing drug</font>     <font color="blue"><font color="blue">manufacturing</font> processes</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our partners, licensees and contract     <font color="blue"><font color="blue">manufacture</font>rs</font> to produce our product <font color="blue">candidates</font> for <font color="blue"><font color="blue">clinical trial</font>s</font> and to     <font color="blue">manufacture</font>, supply, store and distribute any resulting products</td>
    </tr>
    <tr>
      <td>While we have not experienced <font color="blue">problems with</font> our partners, licensees or     <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>rs</font></font> to date, our <font color="blue">reliance on</font> these <font color="blue"><font color="blue">third parties</font> exposes</font>     us  to  the  following  risks, any of which <font color="blue">could delay</font> or prevent the     <font color="blue">completion</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font>, the approval of our product <font color="blue">candidates</font> by     the  FDA or other <font color="blue"><font color="blue">regulatory</font> agencies</font>, or the <font color="blue">commercialization</font> of our     products,  result  in <font color="blue">higher costs</font>, or <font color="blue">deprive us</font> of <font color="blue">potential product</font>     revenues:           •   Drug <font color="blue"><font color="blue">manufacture</font>rs</font> are obliged to operate in <font color="blue"><font color="blue">accordance</font> with</font>     FDA-mandated current good <font color="blue">manufacturing</font> practices, or cGMPs</td>
    </tr>
    <tr>
      <td>A failure of     any of our partners, licensees or <font color="blue">contract <font color="blue"><font color="blue">manufacture</font>rs</font></font> to establish and     <font color="blue">follow cGMPs</font> and to document their adherence to <font color="blue">such practices may lead</font> to     <font color="blue"><font color="blue">significant</font> delays</font> in the <font color="blue">availability</font> of material for <font color="blue"><font color="blue">clinical trial</font>s</font> and     may delay or <font color="blue">prevent filing</font> or approval of <font color="blue">marketing <font color="blue">applications</font></font> for our     products</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Changing </font><font color="blue">contract <font color="blue"><font color="blue">manufacture</font>rs</font></font> may be <font color="blue">difficult</font> and the number of     potential <font color="blue"><font color="blue">manufacture</font>rs</font> is limited</td>
    </tr>
    <tr>
      <td><font color="blue">Changing </font><font color="blue"><font color="blue">manufacture</font>rs</font> may require     re-validation of the <font color="blue"><font color="blue">manufacturing</font> processes</font> and procedures in <font color="blue">accordance</font>     with FDA-mandated cGMPs</td>
    </tr>
    <tr>
      <td>Such re-validation may be costly and     time-consuming</td>
    </tr>
    <tr>
      <td>It may be <font color="blue">difficult</font> or impossible for us to <font color="blue">find replacement</font>     <font color="blue"><font color="blue">manufacture</font>rs</font> on acceptable <font color="blue">terms quickly</font>, or at all</td>
    </tr>
    <tr>
      <td>Drug <font color="blue"><font color="blue">manufacture</font>rs</font> are subject to <font color="blue">ongoing periodic unannounced inspections</font>     by the FDA and <font color="blue">corresponding</font> state and foreign agencies to ensure strict     compliance  with cGMPs, other <font color="blue">government</font> <font color="blue">regulations</font> and <font color="blue">corresponding</font>     foreign standards</td>
    </tr>
    <tr>
      <td>We are not aware of any <font color="blue">violations by</font> our partners,     licensees  or  contract  <font color="blue"><font color="blue">manufacture</font>rs</font>  of any of these <font color="blue">regulations</font> or     standards</td>
    </tr>
    <tr>
      <td>While we are obligated to audit the performance of our <font color="blue">contractor</font>     <font color="blue"><font color="blue">manufacture</font>rs</font>, we do not have <font color="blue">control over</font> their <font color="blue">compliance with</font> these     <font color="blue">regulations</font> and standards</td>
    </tr>
    <tr>
      <td>Failure by our partners, licensees, contract     <font color="blue"><font color="blue">manufacture</font>rs</font> or us to <font color="blue"><font color="blue">comply with</font> applicable</font> <font color="blue">regulations</font> could result                                           20     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>in sanctions that would have a material adverse effect on our business,     including fines, <font color="blue">injunctions</font>, civil penalties, failure of the <font color="blue">government</font> to     <font color="blue">grant premarket approval</font> of drugs, delays, suspension or withdrawal of     approvals,  seizures or recalls of product, operating <font color="blue">restrictions</font> and     criminal <font color="blue">prosecution</font>s</td>
    </tr>
    <tr>
      <td>We or our <font color="blue"><font color="blue">strategic partner</font>s</font> or <font color="blue">licensees may</font> not be able to <font color="blue">manufacture</font> our     product <font color="blue">candidates</font> in commercial quantities, which would prevent us from     <font color="blue">commercializing</font> our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>To date, our product <font color="blue">candidates</font> have been <font color="blue">manufacture</font>d in small quantities     for preclinical and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If any of these product <font color="blue">candidates</font> are     <font color="blue">approved by</font> the FDA or other <font color="blue"><font color="blue">regulatory</font> agencies</font> for <font color="blue">commercial sale</font>, they     will need to be <font color="blue">manufacture</font>d in <font color="blue">larger quantities</font></td>
    </tr>
    <tr>
      <td>We or our strategic     partners  or licensees, as applicable, may not be able to <font color="blue">successfully</font>     increase the <font color="blue">manufacturing</font> <font color="blue">capacity</font>, whether in <font color="blue">collaboration</font> with contract     <font color="blue"><font color="blue">manufacture</font>rs</font> or <font color="blue">independent</font>ly, for any of our product <font color="blue">candidates</font> in a     timely or <font color="blue">economic manner</font>, or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>scale-up of <font color="blue">manufacturing</font>     may require <font color="blue">additional</font> validation studies, which the FDA must review and     approve</td>
    </tr>
    <tr>
      <td>If  we  or our <font color="blue"><font color="blue">strategic partner</font>s</font> or licensees are unable to     <font color="blue">successfully</font> increase the <font color="blue">manufacturing</font> <font color="blue">capacity</font> for a <font color="blue">product candidate</font>,     the <font color="blue"><font color="blue">regulatory</font> approval</font> or <font color="blue">commercial launch</font> of that <font color="blue">product candidate</font> may     be delayed or there may be a shortage in supply</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">candidates</font>     require precise, high quality <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>Failure to achieve and maintain     these high <font color="blue">manufacturing</font> standards, including the incidence of <font color="blue">manufacturing</font>     errors,  could  result  in patient injury or death, product recalls or     <font color="blue">withdrawals</font>,  delays  or failures in product testing or delivery, cost     overruns or other problems that <font color="blue">could seriously hurt</font> our business</td>
    </tr>
    <tr>
      <td>If we are unable to retain and <font color="blue">recruit qualified <font color="blue">scientists</font></font> or if any of our     key executives, <font color="blue">key employees</font> or <font color="blue">key <font color="blue">consultants</font> <font color="blue">discontinue</font>s</font> his or her     <font color="blue">employment</font> or <font color="blue">consulting <font color="blue">relationship</font> with us</font>, it may delay our <font color="blue">development</font>     efforts or <font color="blue">otherwise harm</font> our business</td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> the key members of our <font color="blue">management</font> and scientific     staff, especially our <font color="blue">chief executive officer</font>, Corey Goodman, Ph</td>
    </tr>
    <tr>
      <td>D The loss     of any of our <font color="blue">key employees</font> or <font color="blue">key <font color="blue">consultants</font> could impede</font> the <font color="blue">achievement</font>     of our research and <font color="blue">development</font> objectives</td>
    </tr>
    <tr>
      <td>Furthermore, recruiting and     retaining <font color="blue">qualified scientific personnel</font> to perform research and <font color="blue">development</font>     work in the future is critical to our success</td>
    </tr>
    <tr>
      <td>We may be unable to attract     and  retain  <font color="blue">personnel on</font> acceptable <font color="blue">terms given</font> the <font color="blue"><font color="blue">competition</font> among</font>     <font color="blue">bio<font color="blue">technology</font></font>, <font color="blue">pharmaceutical</font> and health care companies, <font color="blue">universities</font> and     non-profit <font color="blue">research institutions</font> for experienced <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>We maintain     “key man” insurance on Dr</td>
    </tr>
    <tr>
      <td>We do not maintain “key man” insurance     <font color="blue">policies on</font> any of our other officers or employees</td>
    </tr>
    <tr>
      <td>All of our employees are     employed “at will” and, therefore, each employee may leave our <font color="blue">employment</font> at     any time</td>
    </tr>
    <tr>
      <td>We  have  a  history  of  losses  and  we  may never achieve sustained     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Since our inception, we have <font color="blue">incurred <font color="blue">significant</font> net losses</font>, including net     losses of dlra32dtta0 million, dlra39dtta9 million, dlra41dtta9 million, dlra25dtta1 million, and     dlra11dtta4 million, respectively, for the years ended <font color="blue">December </font>31, 2005, 2004,     2003, 2002 and 2001</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our <font color="blue">cumulative net loss</font> was     dlra154dtta0 million</td>
    </tr>
    <tr>
      <td>None of our product <font color="blue">candidates</font> has completed <font color="blue">development</font> or     received  required <font color="blue"><font color="blue">regulatory</font> approval</font>s and, <font color="blue">consequently</font>, we have not     generated revenues from the sale of products and do not expect to do so for     at  least  the  next several years</td>
    </tr>
    <tr>
      <td>Even if one or more of our product     <font color="blue">candidates</font> is <font color="blue">commercialize</font>d, we expect to incur substantial losses for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and sale of our <font color="blue">products will</font> require     <font color="blue">completion</font>  of <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">significant</font> <font color="blue">additional</font> research and     <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur <font color="blue">significant</font></font> operating     and <font color="blue">capital expenditures</font> and anticipate that our <font color="blue">expenses will increase</font>     <font color="blue">substantially</font> in the <font color="blue">foreseeable future</font> as we:           •   expand our research and <font color="blue">development</font> programs; and           •   advance new product <font color="blue">candidates</font> into clinical <font color="blue">development</font> from our     <font color="blue">existing research programs</font></td>
    </tr>
    <tr>
      <td>We also expect to experience <font color="blue">negative cash flow</font> for the <font color="blue">foreseeable future</font>     as we fund our operating losses and <font color="blue">capital expenditures</font></td>
    </tr>
    <tr>
      <td>We will need to     <font color="blue">generate <font color="blue">significant</font> revenues</font> to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our ability to                                           21     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font><font color="blue">generate revenue</font>s and achieve <font color="blue">profitability</font> depends on successful <font color="blue">completion</font>     of <font color="blue"><font color="blue">clinical trial</font>s</font>, our <font color="blue">additional</font> research and <font color="blue">development</font> efforts, our     ability  to  <font color="blue">successfully</font>  <font color="blue">commercially introduce</font> our products, market     <font color="blue">acceptance</font> of our products, the <font color="blue">competitive position</font> of our products and the     other <font color="blue">risk factors set forth</font> in this report</td>
    </tr>
    <tr>
      <td>We may not be able to generate     these revenues, and we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our failure to     achieve, sustain and/or increase <font color="blue">profitability</font> on a quarterly or annual     <font color="blue">basis could negatively impact</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we cannot raise <font color="blue">additional</font> capital on acceptable terms, we may be unable     to  complete  planned  <font color="blue"><font color="blue">clinical trial</font>s</font>, obtain <font color="blue"><font color="blue">regulatory</font> approval</font>s or     <font color="blue">commercialize</font> our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">existing <font color="blue">cash reserves</font> will fund</font> our planned <font color="blue">activities</font> for     more than the next 12 months</td>
    </tr>
    <tr>
      <td>However, we will require substantial future     capital  in order to continue to conduct the research and <font color="blue">development</font>,     clinical and <font color="blue">regulatory</font> <font color="blue">activities</font> <font color="blue">necessary</font> to bring our product <font color="blue">candidates</font>     to market and to establish commercial <font color="blue">manufacturing</font>, sales and marketing     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>During the year ended <font color="blue">December </font>31, 2005, our <font color="blue">net cash used</font> in     operating <font color="blue">activities</font> was dlra19dtta5 million and we had <font color="blue">capital expenditures</font> of     dlra2dtta6  million</td>
    </tr>
    <tr>
      <td>Our future capital <font color="blue"><font color="blue">requirement</font>s</font> <font color="blue">depend on</font> many factors,     including:           •   the progress of preclinical <font color="blue">development</font> and <font color="blue">laboratory testing</font> and     <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   the time and <font color="blue">costs involved</font> in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s;           •   delays that may be caused <font color="blue">by evolving <font color="blue"><font color="blue">requirement</font>s</font></font> of <font color="blue">regulatory</font>     agencies;           •   the number of product <font color="blue">candidates</font> we pursue;           •   the <font color="blue">costs involved</font> in filing and <font color="blue">prosecuting <font color="blue">patent <font color="blue">applications</font></font></font> and     enforcing or <font color="blue">defending patent</font> claims;           •   our plans to establish sales, marketing and/or <font color="blue">manufacturing</font>     <font color="blue">capabilities</font>;           •   our ability to establish, enforce and maintain <font color="blue">selected strategic</font>     alliances and <font color="blue">activities</font> required for product <font color="blue">commercialization</font>;           •   the <font color="blue">acquisition</font> of <font color="blue">technologies</font> or products and other business     <font color="blue">opportunities</font> that require <font color="blue">financial commitments</font>; and           •   our revenues, if any, from successful <font color="blue">development</font> and     <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>We     <font color="blue">face <font color="blue">intense <font color="blue">competition</font></font> from</font> many other companies in the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font>  industry  for  corporate <font color="blue">collaboration</font>s, as well as for     <font color="blue">establishing</font> <font color="blue"><font color="blue">relationship</font>s with</font> academic and <font color="blue">research institutions</font> and for     obtaining licenses to <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to attract     and retain <font color="blue">corporate partners</font> to develop, introduce and market our products,     our business may be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our strategy and any     reliance  on  corporate  partners,  if  we  are able to <font color="blue">establish such</font>     <font color="blue">collaborative <font color="blue">relationship</font>s</font>, are subject to <font color="blue">additional</font> risks</td>
    </tr>
    <tr>
      <td>Our partners     may not <font color="blue">devote sufficient resources</font> to the <font color="blue">development</font>, <font color="blue">introduction</font> and     marketing  of  our  products or may not pursue further <font color="blue">development</font> and     <font color="blue">commercialization</font> of products resulting from <font color="blue">collaboration</font>s with us</td>
    </tr>
    <tr>
      <td>If a     corporate partner elects to terminate its <font color="blue">relationship</font> with us, our ability     to develop, introduce and market our products may be <font color="blue"><font color="blue">significant</font>ly</font> impaired     and we may be forced to <font color="blue">discontinue</font> the product <font color="blue">altogether</font></td>
    </tr>
    <tr>
      <td>The failure of any future <font color="blue">collaboration</font> efforts could have     a material adverse effect on our ability to develop, introduce and market     our products and, <font color="blue">consequently</font>, could have a material adverse effect on our     business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In addition to strategic <font color="blue">collaboration</font>s, we <font color="blue">may seek funding through private</font>     or <font color="blue">public sales</font> of our securities, entering into credit <font color="blue">arrangements</font> or by     licensing all or a portion of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>This funding may <font color="blue"><font color="blue">significant</font>ly</font>     <font color="blue">dilute <font color="blue">existing <font color="blue">stockholders</font></font></font> or may limit our rights to our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>We filed a <font color="blue"><font color="blue">registration statement</font> on</font> Form S-3 with the SEC to be able to     sell from time to time up to dlra100 million worth of any <font color="blue">combination</font> of debt     securities, <font color="blue">common stock</font>, preferred stock and warrants</td>
    </tr>
    <tr>
      <td>The SEC declared     this <font color="blue">registration statement</font> <font color="blue">effective</font> in May 2005</td>
    </tr>
    <tr>
      <td>The <font color="blue">actual sale will</font> be     offered via prospectus in amounts, at prices and at terms determined at the     time of an offering and may be <font color="blue">sold directly by us</font> to investors, through     agents  or <font color="blue">through underwriters</font> or dealers</td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>2005, we sold     4cmam000cmam000 shares of <font color="blue">common stock</font> to the public at dlra13dtta50 per share for gross     proceeds  of dlra54 million</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, dlra46 million remains     <font color="blue">available under</font> this <font color="blue">registration statement</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">additional</font> funding on reasonable terms, or at     all</td>
    </tr>
    <tr>
      <td>If we cannot obtain <font color="blue">adequate funds</font>, we may:           •   terminate or delay preclinical <font color="blue">development</font> or <font color="blue"><font color="blue">clinical trial</font>s</font> for one     or more of our product <font color="blue">candidates</font>;           •   <font color="blue">delay establishment</font>, or fail to establish, sales, marketing and/or     <font color="blue">manufacturing</font> <font color="blue">capabilities</font>;           •   curtail <font color="blue">significant</font> product <font color="blue">development</font> programs that are designed to     identify new product <font color="blue">candidates</font>;           •   not be in a position to acquire <font color="blue">technologies</font> or pursue other business     <font color="blue">opportunities</font> that require <font color="blue">financial commitments</font>; and/or           •   <font color="blue">relinquish rights</font> to our <font color="blue">technologies</font> or product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry        Claims that we infringe a third-party’s <font color="blue">intellectual property</font> may give rise     to <font color="blue">burdensome <font color="blue">litigation</font></font>, result in <font color="blue">potential <font color="blue">liability</font></font> for damages or stop     our <font color="blue">development</font> and <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> assert patent or other <font color="blue">intellectual property</font> <font color="blue">infringement</font>     claims <font color="blue">against us</font> or our <font color="blue"><font color="blue">strategic partner</font>s</font> or licensees <font color="blue">with respect</font> to     <font color="blue">technologies</font> used in our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">conducted patent</font>     searches to determine whether the <font color="blue">technologies</font> used in our <font color="blue">products infringe</font>     patents held <font color="blue">by <font color="blue">third parties</font></font>, we expect that <font color="blue">numerous <font color="blue">patent <font color="blue">applications</font></font></font>     are  <font color="blue">currently pending</font> and may be filed in the future for <font color="blue">technologies</font>     <font color="blue">generally</font> related to our <font color="blue">technologies</font>, including many <font color="blue">patent <font color="blue">applications</font></font>     that <font color="blue">remain <font color="blue">confidential</font></font> after filing</td>
    </tr>
    <tr>
      <td>Due to these factors and the inherent     <font color="blue">un<font color="blue">certainty</font></font> in <font color="blue">conducting patent searches</font>, we may violate third-party patent     rights that we have not yet identified</td>
    </tr>
    <tr>
      <td>US and foreign patents have been issued to <font color="blue">third parties</font> in the same     fields  as  some  of  our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>There may also be patent     <font color="blue">applications</font>  filed by these or other parties in <font color="blue">the <font color="blue"><font color="blue">United States</font> </font></font>and     various foreign <font color="blue">jurisdictions</font> that are in the <font color="blue">same fields as</font> some of our     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">patent <font color="blue">applications</font></font>, if issued, could subject us     to <font color="blue"><font color="blue">infringement</font> actions</font></td>
    </tr>
    <tr>
      <td>Although we have received <font color="blue">communications from</font> a     <font color="blue">third party</font> alleging that we <font color="blue">may infringe certain patents</font> held by the third     party, we do not believe there is a <font color="blue">reasonable basis</font> for an action claiming     that we are infringing any valid and <font color="blue">enforceable patents</font> of such third     party</td>
    </tr>
    <tr>
      <td>To date we have not been subject to any <font color="blue"><font color="blue">infringement</font> actions</font></td>
    </tr>
    <tr>
      <td>The owners or licensees of these and other <font color="blue"><font color="blue">patents may</font> file one</font> or more     <font color="blue"><font color="blue">infringement</font> actions</font> <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> can <font color="blue">involve complex</font>     factual and <font color="blue">legal questions</font> and its outcome is uncertain</td>
    </tr>
    <tr>
      <td>Any claim relating     to <font color="blue">infringement</font> of patents that is <font color="blue">successfully</font> asserted <font color="blue">against us</font> may     cause us to pay substantial damages</td>
    </tr>
    <tr>
      <td>Even  if  we  were  to  prevail,  any  <font color="blue">litigation</font>  could be costly and     time-consuming and <font color="blue">would divert</font> the attention of our <font color="blue">management</font> and key     <font color="blue">personnel from</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, as a result of a patent     <font color="blue">infringement</font> suit brought <font color="blue">against us</font> or our <font color="blue"><font color="blue">strategic partner</font>s</font> or licensees,     we or our <font color="blue"><font color="blue">strategic partner</font>s</font> or <font color="blue">licensees may</font> be forced to stop or delay     developing, <font color="blue">manufacturing</font> or selling <font color="blue"><font color="blue">potential product</font>s</font>, including NXY-059,     that are claimed to infringe a <font color="blue">third party</font>’s <font color="blue">intellectual property</font> unless     that <font color="blue">party grants us</font> or our <font color="blue"><font color="blue">strategic partner</font>s</font> or <font color="blue">licensees rights</font> to use     its <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>In such cases, we may be required to obtain     licenses to patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of others in order to continue to     <font color="blue">commercialize</font>  our products</td>
    </tr>
    <tr>
      <td>However, we may not be able to obtain any     licenses required under any patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font>     on acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue"><font color="blue">strategic partner</font>s</font>, licensees or     we were able to obtain rights to the third                                           23     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>party’s <font color="blue">intellectual property</font>, these <font color="blue">rights may</font> be non-exclusive, thereby     giving our <font color="blue"><font color="blue">competitor</font>s</font> access to the same <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>Ultimately,     we may be unable to <font color="blue">commercialize</font> some of our <font color="blue"><font color="blue">potential product</font>s</font> or may have     to <font color="blue">discontinue</font> <font color="blue">development</font> of a <font color="blue">product candidate</font>, such as NXY-059 or cease     some of our business <font color="blue">operations</font> as a result of patent <font color="blue">infringement</font> claims,     which could <font color="blue">severely harm</font> our business</td>
    </tr>
    <tr>
      <td>We may be subject to damages resulting from claims that we or our employees     have <font color="blue">wrongfully used</font> or disclosed alleged <font color="blue">trade secrets</font> of their former     employers</td>
    </tr>
    <tr>
      <td>Many of our employees were <font color="blue">previously</font> employed at <font color="blue">universities</font> or other     <font color="blue">bio<font color="blue">technology</font></font> or <font color="blue">pharmaceutical</font> companies, including our <font color="blue"><font color="blue">competitor</font>s</font> or     potential <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Although no claims <font color="blue">against us</font> are <font color="blue">currently pending</font>,     we may be subject to claims that these employees or we have <font color="blue">inadvertently</font> or     otherwise used or disclosed <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information     of their <font color="blue">former employers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font> to <font color="blue">defend against</font>     these claims</td>
    </tr>
    <tr>
      <td>Even if we are successful in <font color="blue">defending against</font> these claims,     <font color="blue">litigation</font>  could  result in substantial costs and be a <font color="blue">distraction</font> to     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>If we fail in <font color="blue">defending such</font> claims, in addition to <font color="blue">paying money</font>     claims, we may lose valuable <font color="blue">intellectual property</font> rights or personnel</td>
    </tr>
    <tr>
      <td>A     loss of <font color="blue">key research personnel</font> or their work <font color="blue">product could hamper</font> or prevent     our  ability  to <font color="blue">commercialize</font> certain product <font color="blue">candidates</font>, which could     <font color="blue">severely harm</font> our business</td>
    </tr>
    <tr>
      <td>If  we  are  unable  to  protect our <font color="blue">intellectual property</font> rights, our     <font color="blue"><font color="blue">competitor</font>s</font> may develop and <font color="blue">market products with</font> similar features that may     <font color="blue">reduce demand</font> for our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors</font> are important to our success:           •   receiving <font color="blue">patent protection</font> for our product <font color="blue">candidates</font>;           •   not <font color="blue">infringing on</font> the <font color="blue">intellectual property</font> rights of others;           •   <font color="blue">preventing others from infringing</font> our <font color="blue">intellectual property</font> rights;     and           •   maintaining our <font color="blue">patent rights</font> and <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We will be able to protect our <font color="blue">intellectual property</font> rights in patents and     <font color="blue">trade secrets</font> from unauthorized use <font color="blue">by <font color="blue">third parties</font></font> only to the extent that     such <font color="blue">intellectual property</font> rights are <font color="blue">covered by valid</font> and enforceable     patents or are <font color="blue">effective</font>ly maintained as <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We try to protect our <font color="blue">proprietary</font> position by filing US and foreign patent     <font color="blue">applications</font>  related  to  our  <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font>, <font color="blue">inventions</font> and     <font color="blue">improvements</font> that are important to the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td><font color="blue">Because     </font>the patent position of <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical</font> companies involves     complex legal and factual questions, the issuance, scope and <font color="blue">enforceability</font>     of patents cannot be predicted with <font color="blue">certainty</font></td>
    </tr>
    <tr>
      <td>Patents, if issued, may be     challenged,  invalidated  or  <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>US  patents  and patent     <font color="blue">applications</font>  may also be subject to interference <font color="blue">proceedings</font> and US     <font color="blue">patents may</font> be subject to <font color="blue">reexamination</font> <font color="blue">proceedings</font> in the US Patent and     Trademark  Office (and foreign <font color="blue">patents may</font> be subject to opposition or     comparable <font color="blue">proceedings</font> in the <font color="blue">corresponding</font> foreign patent office), which     <font color="blue">proceedings</font> could result in <font color="blue">either loss</font> of the patent or denial of the     <font color="blue">patent application</font> or loss or reduction in the scope of one or more of the     claims of the patent or <font color="blue">patent application</font></td>
    </tr>
    <tr>
      <td>In addition, such interference,     <font color="blue">reexamination</font> and opposition <font color="blue">proceedings</font> may be costly</td>
    </tr>
    <tr>
      <td>Thus, any patents     that we own or license from others may not provide any protection against     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Our pending <font color="blue">patent <font color="blue">applications</font></font>, those we may file in the     future or those we may license from third <font color="blue">parties may</font> not result in patents     being issued</td>
    </tr>
    <tr>
      <td>If issued, they may not provide us with <font color="blue">proprietary</font> protection     or <font color="blue"><font color="blue">competitive advantage</font>s</font> against <font color="blue"><font color="blue">competitor</font>s</font> with similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Furthermore,  others may <font color="blue">independent</font>ly develop similar <font color="blue">technologies</font> or     duplicate any <font color="blue">technology</font> that we have developed</td>
    </tr>
    <tr>
      <td>We rely on third-party     payment services for the payment of <font color="blue">foreign patent annuities</font> and other fees</td>
    </tr>
    <tr>
      <td>Non-payment  or  delay in payment of such fees, whether <font color="blue">intentional</font> or     un<font color="blue">intentional</font>, may result in loss of patents or <font color="blue">patent rights</font> important to     our business</td>
    </tr>
    <tr>
      <td>Many countries, including <font color="blue">certain countries</font> in Europe, have <font color="blue">compulsory</font>     <font color="blue">licensing laws under which</font> a <font color="blue">patent owner</font> may be compelled to <font color="blue">grant licenses</font>     to <font color="blue">third parties</font> (for example, the <font color="blue">patent owner</font> has failed to “work” the                                           24     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>invention in that country, or the <font color="blue">third party</font> has patented <font color="blue">improvements</font>)</td>
    </tr>
    <tr>
      <td>In     addition,  many  <font color="blue">countries limit</font> the <font color="blue">enforceability</font> of <font color="blue">patents against</font>     <font color="blue">government</font> agencies or <font color="blue">government</font> <font color="blue">contractor</font>s</td>
    </tr>
    <tr>
      <td>In these countries, the     <font color="blue">patent owner</font> may have limited remedies, which could <font color="blue">materially</font> diminish the     value of the patent</td>
    </tr>
    <tr>
      <td><font color="blue">Compulsory </font>licensing of life-saving drugs is also     <font color="blue">becoming increasingly popular</font> in developing <font color="blue">countries either through direct</font>     <font color="blue">legislation</font> or <font color="blue"><font color="blue">international</font> <font color="blue">initiatives</font></font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">compulsory</font> licenses could be     extended to include some of our product <font color="blue">candidates</font>, which <font color="blue">could limit</font> our     potential revenue <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>Moreover, the legal systems of certain     countries, <font color="blue">particularly</font> certain developing countries, do not favor the     <font color="blue">aggressive</font> <font color="blue">enforcement</font> of patent and other <font color="blue">intellectual property</font> protection     which makes it <font color="blue">difficult</font> to stop <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>In addition, our ability to enforce our <font color="blue">patent rights</font> depends on our ability     to detect <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">difficult</font> to detect infringers who do not     advertise the compounds that are used in their products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> to     enforce or defend our <font color="blue">patent rights</font>, even if we were to prevail, could be     costly and time-consuming and <font color="blue">would divert</font> the attention of our <font color="blue">management</font>     and key <font color="blue">personnel from</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  also rely on <font color="blue">trade secrets</font>, know-how and <font color="blue">technology</font>, which are not     protected  by patents, to maintain our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>We try to     protect this information by entering into <font color="blue">confidential</font>ity <font color="blue">agreements</font> with     parties  that  have  access  to  it,  such  as our <font color="blue"><font color="blue">strategic partner</font>s</font>,     collaborators, employees and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">parties may</font> breach     these  <font color="blue">agreements</font>  and  disclose  our  <font color="blue">confidential</font> information or our     <font color="blue"><font color="blue">competitor</font>s</font> might learn of the information in some other way</td>
    </tr>
    <tr>
      <td>If any trade     secret, know-how or other <font color="blue">technology</font> not <font color="blue">protected by</font> a patent were to be     disclosed to or <font color="blue">independent</font>ly developed by a <font color="blue">competitor</font>, our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could be <font color="blue">materially</font> <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font>and third-party payors may impose sales and <font color="blue">pharmaceutical</font>     pricing <font color="blue">restrictions</font> or controls on our <font color="blue"><font color="blue">potential product</font>s</font> that <font color="blue">could limit</font>     our <font color="blue">future product</font> revenues and <font color="blue">adversely</font> affect <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our <font color="blue"><font color="blue">potential product</font>s</font> is <font color="blue">substantially</font> dependent     on whether third-party <font color="blue">reimbursement</font> is available for the ordering of our     <font color="blue">products by</font> the <font color="blue">medical profession</font> for use by their patients</td>
    </tr>
    <tr>
      <td>Medicare,     Medicaid, health maintenance <font color="blue">organizations</font> and other third-party payors may     not cover or <font color="blue">provide adequate payment</font> for our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>They may     not view our <font color="blue"><font color="blue">potential product</font>s</font> as cost-<font color="blue">effective</font> and <font color="blue"><font color="blue">reimbursement</font> may</font> not     be available to consumers or may not be sufficient to allow our potential     products to be <font color="blue">marketed on</font> a <font color="blue">competitive basis</font></td>
    </tr>
    <tr>
      <td>Likewise, <font color="blue">legislative</font> or     <font color="blue">regulatory</font>  efforts  to  control or <font color="blue">reduce health care costs</font> or reform     <font color="blue">government</font> health care programs could result in <font color="blue">lower prices</font> or rejection of     our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">reimbursement</font> policies or health care     cost <font color="blue">containment</font> <font color="blue">initiatives</font> that limit or restrict <font color="blue">reimbursement</font> for our     products may cause our <font color="blue">future product</font> revenues, if any, to decline</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical</font> <font color="blue">industries</font> is intense,     and if we fail to compete <font color="blue">effective</font>ly our financial results will suffer</td>
    </tr>
    <tr>
      <td>Our  business  is  <font color="blue">characterized</font>  by extensive research efforts, rapid     <font color="blue">development</font>s  and <font color="blue">intense <font color="blue">competition</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> may have or may     develop superior <font color="blue">technologies</font> or approaches to the <font color="blue">development</font> of competing     products, which may provide them with <font color="blue"><font color="blue">competitive advantage</font>s</font></td>
    </tr>
    <tr>
      <td>Our potential     products  may  not  compete  <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We believe that successful     <font color="blue">competition</font>  in  our  industry  depends  on  product efficacy, safety,     re<font color="blue">liability</font>, <font color="blue">availability</font>, timing, scope of <font color="blue"><font color="blue">regulatory</font> approval</font>, <font color="blue">acceptance</font>     and price, among other things</td>
    </tr>
    <tr>
      <td><font color="blue">Important </font>factors to our <font color="blue">success also</font> include     speed in developing product <font color="blue">candidates</font>, completing clinical <font color="blue">development</font> and     <font color="blue">laboratory testing</font>, obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s and <font color="blue">manufacturing</font> and     <font color="blue">selling commercial quantities</font> of <font color="blue"><font color="blue">potential product</font>s</font> to the market</td>
    </tr>
    <tr>
      <td>We expect <font color="blue">competition</font> to <font color="blue">increase as <font color="blue">technological</font> advances</font> are made and     commercial <font color="blue">applications</font> broaden</td>
    </tr>
    <tr>
      <td>In <font color="blue">commercializing</font> our <font color="blue">initial product</font>     <font color="blue">candidates</font> and any <font color="blue">additional</font> product <font color="blue">candidates</font>, we will face substantial     <font color="blue">competition</font>  from  <font color="blue">pharmaceutical</font>,  <font color="blue">bio<font color="blue">technology</font></font> and other companies,     <font color="blue">universities</font> and <font color="blue">research institutions</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>Many  of our <font color="blue"><font color="blue">competitor</font>s</font> have <font color="blue">substantially</font> greater capital resources,     research and <font color="blue">development</font> staffs, <font color="blue">facilities</font> and experience in conducting     clinical  trials  and  obtaining  <font color="blue">regulatory</font>  approvals, as well as in     <font color="blue">manufacturing</font> and marketing <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">competitor</font>s</font>     may achieve product <font color="blue">commercialization</font> or <font color="blue">patent protection</font> earlier than we     achieve <font color="blue">commercialization</font> or <font color="blue">patent protection</font>, if at all</td>
    </tr>
    <tr>
      <td>Furthermore, we     believe that some of our <font color="blue"><font color="blue">competitor</font>s</font> have used, and <font color="blue">may continue</font> to use,     <font color="blue">litigation</font> to gain a <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>Rapid <font color="blue">technological</font> change could make our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>Bio<font color="blue">pharmaceutical</font> <font color="blue">technologies</font> have <font color="blue">undergone rapid</font> and <font color="blue">significant</font> change     and we expect that they <font color="blue">will continue</font> to do so</td>
    </tr>
    <tr>
      <td>Any compounds, products or     processes that we or our <font color="blue"><font color="blue">strategic partner</font>s</font> or licensees develop may become     obsolete  or uneconomical before achieving <font color="blue">significant</font> revenues</td>
    </tr>
    <tr>
      <td><font color="blue">Rapid     </font><font color="blue">technological</font> change <font color="blue">could also</font> make our <font color="blue">products obsolete</font> or uneconomical</td>
    </tr>
    <tr>
      <td>We face <font color="blue">potential product</font> <font color="blue">liability</font> exposure far in excess of our limited     <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>The use of any of our product <font color="blue">candidates</font> in <font color="blue"><font color="blue">clinical trial</font>s</font>, and the sale of     any approved products, may expose us to <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>claims  might  be  made  directly by consumers, health care providers,     <font color="blue">pharmaceutical</font> companies or <font color="blue">others selling</font> our products</td>
    </tr>
    <tr>
      <td>We have obtained     limited <font color="blue">product <font color="blue">liability</font></font> <font color="blue">insurance coverage</font> for our <font color="blue"><font color="blue">clinical trial</font>s</font> in the     amount  of  dlra5 million per occurrence and dlra5 million in the aggregate</td>
    </tr>
    <tr>
      <td>However, our <font color="blue">insurance may</font> not <font color="blue">reimburse us</font> or may not be sufficient to     <font color="blue">reimburse us</font> for expenses or losses we may suffer</td>
    </tr>
    <tr>
      <td>Moreover, insurance     coverage is becoming increasingly expensive, and we may not be able to     maintain <font color="blue">insurance coverage</font> at a <font color="blue">reasonable cost</font> or in <font color="blue">sufficient amounts</font> to     <font color="blue">protect us against losses due</font> to <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>If we obtain marketing approval     for any of our product <font color="blue">candidates</font> in <font color="blue">development</font>, we intend to expand our     <font color="blue">insurance coverage</font> to include the sale of <font color="blue">commercial product</font>s, but we may be     unable to obtain commercially reasonable <font color="blue">product <font color="blue">liability</font></font> insurance for any     <font color="blue">products approved</font> for marketing</td>
    </tr>
    <tr>
      <td>On occasion, juries have awarded large     judgments in class <font color="blue">action lawsuits based on drugs</font> that had <font color="blue">unanticipated</font>     side effects</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">industries</font>,     in general, have been subject to <font color="blue">significant</font> medical malpractice <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>A successful <font color="blue">product <font color="blue">liability</font></font> claim or series of claims brought <font color="blue">against us</font>     <font color="blue">would decrease</font> our <font color="blue">cash reserves</font> and could cause our stock price to fall</td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font> involve <font color="blue">hazardous materials</font> and we may be liable for any     resulting <font color="blue">contamination</font> or injuries</td>
    </tr>
    <tr>
      <td>Our research <font color="blue">activities</font> involve the use of <font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>We cannot     eliminate  the  risk  of <font color="blue">accident</font>al <font color="blue">contamination</font> or <font color="blue">injury from</font> these     materials</td>
    </tr>
    <tr>
      <td>If  an <font color="blue">accident</font> occurs, we may be liable for any resulting     damages, which may decrease our <font color="blue">cash reserves</font> and could cause our stock     price to fall</td>
    </tr>
    <tr>
      <td>If  we are unable to complete our <font color="blue">assessment</font> as to the adequacy of our     internal <font color="blue">control over</font> financial reporting within the required time periods     as required by Section 404 of the Sarbanes-Oxley Act of 2002, or in the     course of <font color="blue">such <font color="blue">assessment</font>s</font> identify and report material <font color="blue">weaknesses</font> in our     controls, our <font color="blue">investors could lose confidence</font> in the re<font color="blue">liability</font> of our     financial statements, which could result in a decrease in the value of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As <font color="blue">directed by</font> Section 404 of the Sarbanes-Oxley Act of 2002, the Securities     and Exchange Commission <font color="blue">adopted rules</font> requiring <font color="blue">public companies</font> to include     a report of <font color="blue">management</font> on the company’s <font color="blue"><font color="blue">internal controls over</font> financial</font>     reporting in their <font color="blue">Annual Reports </font>on Form 10-K This report is required to     contain an <font color="blue">assessment</font> by <font color="blue">management</font> of the <font color="blue">effective</font>ness of the company’s     <font color="blue"><font color="blue">internal controls over</font> financial</font> reporting</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">independent</font>     <font color="blue">registered public <font color="blue">accounting</font> firm auditing</font> a public company’s financial     <font color="blue">statements must attest</font> to and report on <font color="blue">management</font>’s <font color="blue">assessment</font> of the     <font color="blue">effective</font>ness of the company’s <font color="blue"><font color="blue">internal controls over</font> financial</font> reporting</td>
    </tr>
    <tr>
      <td>Although our <font color="blue">management</font> has determined, and our <font color="blue">independent</font> registered     public  <font color="blue">accounting</font>  firm  has attested, that our internal <font color="blue">control over</font>     financial reporting was <font color="blue">effective</font> as of <font color="blue">December </font>31, 2005, and we intend to     continue to <font color="blue">diligently</font> and <font color="blue">vigorously review</font> our <font color="blue">internal controls over</font>     financial reporting in order to ensure                                           26     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font><font color="blue">compliance with</font> the Section 404 <font color="blue"><font color="blue">requirement</font>s</font> if our <font color="blue">independent</font> registered     public <font color="blue">accounting</font> firm is not satisfied in the <font color="blue">future with</font> our internal     <font color="blue">controls over financial</font> reporting or the <font color="blue">level at which</font> these controls are     documented, designed, operated or reviewed, or if said <font color="blue">firm interprets</font> the     <font color="blue"><font color="blue">requirement</font>s</font>,  rules or <font color="blue">regulations</font> differently from us, then they may     decline to attest to <font color="blue">management</font>’s <font color="blue">assessment</font> or may issue a report that is     qualified  or has a <font color="blue">scope limitation</font></td>
    </tr>
    <tr>
      <td>We anticipate to <font color="blue">continue expend</font>     resources in developing the <font color="blue">necessary</font> documentation and <font color="blue">testing procedures</font>     required by SOX 404; however, there is a risk that in the future we will not     <font color="blue">comply with</font> all of the <font color="blue"><font color="blue">requirement</font>s</font> imposed by Section 404</td>
    </tr>
    <tr>
      <td>In addition, the     very limited sized of our <font color="blue">organization could lead</font> to <font color="blue">conditions</font> that could     be considered material <font color="blue">weaknesses</font>, such as those related to <font color="blue">segregation</font> of     duties that is possible in larger <font color="blue">organizations</font> but <font color="blue"><font color="blue">significant</font>ly</font> more     <font color="blue">difficult</font> in smaller <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Also, controls related to our general     information <font color="blue">technology</font> infrastructure may not be <font color="blue">as comprehensive as</font> in the     case of a <font color="blue">larger organization with</font> more sophisticated <font color="blue">capabilities</font> and more     extensive  resources</td>
    </tr>
    <tr>
      <td>It is not <font color="blue">clear how such circumstances could</font> be     interpreted  in the future in the context of an <font color="blue">assessment</font> of internal     <font color="blue">controls over financial</font> reporting</td>
    </tr>
    <tr>
      <td>If we fail to implement required new or     <font color="blue">improved controls</font>, we may be unable to <font color="blue">comply with</font> the <font color="blue"><font color="blue">requirement</font>s</font> of     Section 404 in in the future</td>
    </tr>
    <tr>
      <td>This could result in an <font color="blue">adverse reaction</font> in     the <font color="blue">financial markets due</font> to a loss of confidence in the re<font color="blue">liability</font> of our     financial statements, which could cause the <font color="blue">market price</font> of our <font color="blue">common stock</font>     to decline or <font color="blue">could limit</font> our ability to obtain <font color="blue">additional</font> financing</td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock        We expect that our stock price will fluctuate <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">active public market</font> for our <font color="blue">common stock</font> may not develop     or  be  sustained</td>
    </tr>
    <tr>
      <td>The stock market, <font color="blue">particularly</font> in <font color="blue">recent years</font>, has     experienced   <font color="blue">significant</font>  <font color="blue">volatility</font>  <font color="blue">particularly</font>  with  respect  to     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> stocks</td>
    </tr>
    <tr>
      <td>The <font color="blue">volatility</font> of <font color="blue">pharmaceutical</font>     and <font color="blue">bio<font color="blue">technology</font></font> stocks often does not relate to the operating performance     of the <font color="blue">companies represented by</font> the stock</td>
    </tr>
    <tr>
      <td>Factors that could cause this     <font color="blue">volatility</font> in the <font color="blue">market price</font> of our <font color="blue">common stock</font> include:           •   the results from our <font color="blue">clinical trial</font> programs, including the clinical     <font color="blue">trials involving</font> NXY-059 and any <font color="blue">future trials</font> we may conduct;           •   FDA or <font color="blue">international</font> <font color="blue">regulatory</font> actions;           •   failure of any of our product <font color="blue">candidates</font>, if approved, to achieve     <font color="blue">commercial success</font>;           •   <font color="blue">announcements</font> of the <font color="blue">introduction</font> of <font color="blue">new products</font> by us or our     <font color="blue"><font color="blue">competitor</font>s</font>;           •   market <font color="blue">conditions</font> in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> sectors;           •   <font color="blue">development</font>s concerning <font color="blue">intellectual property</font> rights;           •   <font color="blue">litigation</font> or public concern about the safety of our potential     products;           •   <font color="blue">comments by securities analysts</font>;           •   actual and anticipated <font color="blue">fluctuations</font> in our quarterly operating     results;           •   <font color="blue">deviations</font> in our operating results from the estimates of securities     analysts;           •   rumors relating to us or our <font color="blue"><font color="blue">competitor</font>s</font>;           •   <font color="blue">additions</font> or <font color="blue">departures</font> of <font color="blue">key personnel</font>;           •   <font color="blue">third party</font> <font color="blue">reimbursement</font> policies; and           •   <font color="blue">development</font>s concerning current or <font color="blue">future strategic</font> alliances</td>
    </tr>
    <tr>
      <td>These and other <font color="blue">external factors may</font> cause the <font color="blue">market price</font> and demand for     our <font color="blue">common stock</font> to fluctuate <font color="blue">substantially</font>, which may limit or prevent     <font color="blue">investors from readily selling</font> their shares of <font color="blue">common stock</font> and may                                           27     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font><font color="blue">otherwise negatively affect</font> the liquidity of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition,     in the past, when the <font color="blue">market price</font> of a stock has been volatile, holders of     that stock have <font color="blue">instituted securities</font> class action <font color="blue">litigation</font> against the     company that issued the stock</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue"><font color="blue">stockholders</font> brought</font> a lawsuit     <font color="blue">against us</font>, we <font color="blue">could incur</font> substantial <font color="blue">costs defending</font> the lawsuit</td>
    </tr>
    <tr>
      <td>Such a     lawsuit <font color="blue">could also</font> divert the time and attention of our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Future sales of <font color="blue">common stock</font> by our <font color="blue"><font color="blue">existing <font color="blue">stockholders</font></font> may</font> cause our     stock price to fall</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> could decline as a result of sales by     our <font color="blue">existing <font color="blue">stockholders</font></font> of shares of <font color="blue">common stock</font> in the market, or the     <font color="blue">perception</font> that these <font color="blue">sales could</font> occur</td>
    </tr>
    <tr>
      <td>These <font color="blue">sales might also</font> make it more     <font color="blue">difficult</font> for us to <font color="blue">sell equity securities at</font> a time and price that we deem     <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">directors</font> and <font color="blue">management</font> exercise <font color="blue">significant</font> <font color="blue">control over</font> our company</td>
    </tr>
    <tr>
      <td>If  acting  together,  our  <font color="blue">directors</font> and <font color="blue">executive officers</font> and their     <font color="blue">affiliates</font>  can  influence  our <font color="blue">management</font> and affairs and all matters     requiring <font color="blue">stockholder approval</font>, including the election of <font color="blue">directors</font> and     approval  of <font color="blue">significant</font> corporate <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font> of     <font color="blue">ownership may</font> have the effect of delaying or preventing a change in control     of our company and <font color="blue">might affect</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Provisions </font>of <font color="blue">Delaware </font></font>law or our <font color="blue">charter documents</font> and <font color="blue">stockholder rights</font>     plan <font color="blue">could delay</font> or prevent an <font color="blue">acquisition</font> of our company, even if the     <font color="blue">acquisition</font> would be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font>, and could make it more     <font color="blue">difficult</font> for <font color="blue">stockholders</font> to change <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws may discourage,     delay or prevent a merger, <font color="blue">acquisition</font> or other change in control that     <font color="blue">stockholders</font>  may  consider favorable, including <font color="blue">transactions</font> in which     <font color="blue">stockholders</font> might otherwise receive a premium for their shares</td>
    </tr>
    <tr>
      <td>This is     because these <font color="blue">provisions may prevent</font> or frustrate attempts by <font color="blue">stockholders</font>     to replace or remove our current <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>These provisions include:           •   a <font color="blue">classified board</font> of <font color="blue">directors</font>;           •   a prohibition on stockholder action through written consent;           •   a <font color="blue">requirement</font> that <font color="blue">special meetings</font> of <font color="blue">stockholders</font> be <font color="blue">called only by</font>     (i) the Chairman of the Board of Directors, (ii) the Chief Executive     Officer, or (iii) <font color="blue">the <font color="blue">Board of Directors </font></font>pursuant to a <font color="blue">resolution adopted by</font>     a majority of the total number of authorized <font color="blue">directors</font>;           •   advance notice <font color="blue"><font color="blue">requirement</font>s</font> for <font color="blue">stockholder proposals</font> and <font color="blue">nominations</font>;           •   a <font color="blue">requirement</font> of approval of not less than 66^ 2/3prca of all outstanding     shares of our <font color="blue"><font color="blue">capital stock</font> entitled</font> to vote to amend any <font color="blue">bylaws by</font>     stockholder action, or to <font color="blue">amend certain provisions</font> of our <font color="blue">certificate</font> of     <font color="blue">incorporation</font>; and           •   the authority of <font color="blue">the <font color="blue">Board of Directors </font></font>to issue preferred stock with     such terms as <font color="blue">the <font color="blue">Board of Directors </font></font>may determine</td>
    </tr>
    <tr>
      <td>As a result, these provisions and others <font color="blue">available under</font> <font color="blue">Delaware </font>law could     limit the price that investors are willing to pay in the future for shares     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, in March 2005, we adopted a <font color="blue">stockholder rights</font> plan</td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>the rights plan will not prevent a takeover, it is intended to encourage     anyone seeking to acquire our company to negotiate with our board prior to     attempting a takeover by <font color="blue">potentially</font> <font color="blue"><font color="blue">significant</font>ly</font> diluting an acquirer’s     ownership interest in our outstanding <font color="blue">capital stock</font></td>
    </tr>
    <tr>
      <td>The existence of the     rights plan may also discourage <font color="blue">transactions</font> that <font color="blue">otherwise could involve</font>     payment of a premium over prevailing <font color="blue">market price</font>s for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>We have <font color="blue">never paid dividends on</font> our <font color="blue">capital stock</font>, and we do not anticipate     paying any <font color="blue">cash dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">prohibited from</font>     <font color="blue">paying dividends</font>, other <font color="blue">than dividends payable solely</font> in <font color="blue">common stock</font>, by     the <font color="blue">covenants contained</font> in loan <font color="blue">agreements</font> with GATX Ventures, Inc, and     <font color="blue">Transamerica Commercial Finance Corporation</font></td>
    </tr>
    <tr>
      <td>We have paid no <font color="blue">cash dividends</font> on any of our classes of <font color="blue">capital stock</font> to     date and we <font color="blue">currently intend</font> to retain our <font color="blue">future earnings</font>, if any, to fund     the <font color="blue">development</font> and growth of our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>In addition, the terms of     <font color="blue">existing debts preclude us from paying</font> these dividends</td>
    </tr>
    <tr>
      <td>As a result, capital     <font color="blue">appreciation</font>, if any, of our <font color="blue">common stock</font> will be your sole source of gain     for the <font color="blue">foreseeable future</font></td>
    </tr>
  </tbody>
</table>